Ensacove is approved for ALK-positive NSCLC patients who haven't received prior ALK-inhibitors, offering a new first-line treatment option. The eXALT3 trial showed Ensacove significantly improved ...

1 Day ALK -1.46% DJIA -0.97% S&P 500 -1.07% Transportation/Logistics 3.25% ...

A benefit of using Ferticell® Pro Phos 2™ 0-20-0 is its application as foliar is 95+% applied is not only available (it is already in a useable form that needs no conversion), but used.

The Tulsa, Oklahoma-based company said in a news release that the completion of MB-6 increases the company's fractionation capacity to more than one million bpd, “reducing the need for third ...

Mike Whitaker announced that he would step down on Trump's inauguration day.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report 2024 13 March 2025 at 4.00 p.m.: Annual General Meeting ALK ...

Mining operations at the Tomingley Gold Operations; exploration and evaluation activities on tenements held by the group; and pursuing strategic investments in gold exploration companies.

Ginsenoside AD-2 Ameliorating Lipopolysaccharide-Induced Activation in HSC-T6 Cells and Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice via Regulation of VD-VDR Axis.